Saudi Arabia · Delayed Price · Currency is SAR Specialized Medical Company Earnings Call Transcripts
Fiscal Year 2026
-
Q1 2026 saw resilient financial and operational results, with revenue and profit growth driven by improved utilization and expansion of acute and outpatient services. Despite sector-wide seasonality and regional disruptions, margins improved and guidance for the year remains unchanged.
Fiscal Year 2025
-
Net revenue grew 7% year-over-year to SAR 1.54 billion in 2025, with net profit up 43.7% to SAR 266.2 million, including a SAR 60.6 million one-off gain. Outlook for 2026 anticipates continued growth, with revenue guidance of SAR 1.6–1.7 billion and EBITDA margin of 23%–25%.
-
Q3 2025 saw strong revenue and profit growth, driven by a strategic shift to acute and outpatient services, with EBITDA margin rising to 27.3%. Expansion continues with new clinics and hospitals, a SAR 200 million special dividend, and robust guidance for year-end.